Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282672 · ClinicalTrials.gov registry record · NA
Ablation of Intestinal Metaplasia Containing Dysplasia
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 127
- Enrollment target
NCT00282672 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 127 participants.
The verdict
NCT00282672, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett's Esophagus.
Interventions
- DEVICE Ablation System plus anti-secretory medication
- DEVICE Sham procedure plus anti-secretory medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2006-02 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282672
The ClinicalTrials.gov registry entry for NCT00282672 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ablation System plus anti-secretory medication is the first listed.
NCT00282672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282672 about?
NCT00282672 is a clinical study titled "Ablation of Intestinal Metaplasia Containing Dysplasia". The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett's Esophagus.
What is the current status of trial NCT00282672?
This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2006-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00282672?
The interventions under investigation include: Ablation System plus anti-secretory medication (DEVICE), Sham procedure plus anti-secretory medication (DEVICE).
Who is sponsoring clinical trial NCT00282672?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.